The DOI matches its Crossref record.
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Open accessAbstract
The main iron chelator used for transfusional iron overload is desferrioxamine, which is expensive, has toxic side effects, and has to be given subcutaneously. An orally active iron chelator is therefore required. The effects of oral 1,2-dimethyl-3-hydroxypyrid-4-one on urinary iron excretion were studied in eight patients who had received multiple transfusions: four had myelodysplasia and four beta thalassaemia major. Different daily doses of the drug up to 100 mg/kg/day, alone or in combination with ascorbic acid, were used. In three patients with thalassaemia the effect of the drug was compared with that of subcutaneous desferrioxamine at the same daily dose. In all eight patients a single dose of oral 1,2-dimethyl-3-hydroxypyrid-4-one resulted in substantial urinary iron excretion, mainly in the first 12 hours. Urinary iron excretion increased with the dose and with the degree of iron loading of the patient. Giving two or three divided doses over 24 hours resulted in higher urinary iron excretion than a single dose of the same amount over the same time. In most patients coadministration of oral ascorbic acid further increased urinary iron excretion. 1,2-Dimethyl-3-hydroxypyrid-4-one caused similar iron excretion to that achieved with subcutaneous desferrioxamine at a comparable dose. In some cases the iron excretion was sufficiently high (maximum 99 mg/day) to suggest that a negative iron balance could be easily achieved with these protocols in patients receiving regular transfusions. No evidence of toxicity was observed on thorough clinical examination or haematological and biochemical testing in any of the patients. None of the patients had any symptoms that could be ascribed to the drug. These results suggest that the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one is as effective as subcutaneous desferrioxamine in increasing urinary iron excretion in patients loaded with iron. Its cheap synthesis, oral activity, and lack of obvious toxicity at effective doses suggest that it should be developed quickly and thoroughly tested for the management of transfusional iron overload.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Iron-Chelating Therapy and the Treatment of Thalassemia
Olivieri, N. F., & Brittenham, G. M. (1997) · Blood · doi:10.1182/blood.v89.3.739 · Cited by 1,089
Modell, B., Khan, M., Darlison, M., Westwood, M. A., Ingram, D., & Pennell, D. J. (2008) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-10-42 · Cited by 600
A delicate balance: Iron metabolism and diseases of the brain
Hare, D., Ayton, S., Bush, A., & Lei, P. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00034 · Cited by 443
Rachmilewitz, E. A., & Giardina, P. J. (2011) · Blood · doi:10.1182/blood-2010-08-300335 · Cited by 417
Protection against tissue damage in vivo by desferrioxamine: What is its mechanism of action?
Halliwell, B. (1989) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(89)90145-7 · Cited by 378
Metadata
- Authors
- Kontoghiorghes, G. J., Aldouri, M. A., Hoffbrand, A. V., Barr, J., Wonke, B., Kourouclaris, T., & Sheppard, L.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1987-12-12
- Volume
- 295
- Issue
- 6612
- Pages
- 1509-1512
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2081568231
- Cited by
- 187
- References
- 0
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. https://app.cochat.ai/papers/10.1136/bmj.295.6612.1509
- The paper
- Kontoghiorghes, G. J., Aldouri, M. A., Hoffbrand, A. V., Barr, J., Wonke, B., Kourouclaris, T., & Sheppard, L. (1987). Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. BMJ. https://doi.org/10.1136/bmj.295.6612.1509
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.